Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690948 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
A Phase 1 study, sponsored by Anne Chang.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02690948 is a Phase 1 study that has completed, run by Anne Chang. The registered enrollment target is 16 participants.
The verdict
NCT02690948, a Phase 1 study, has completed, sponsored by Anne Chang.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint inhibitors that stimulate immune response. Vismodegib may stop the growth of tumor cells by blocking signals needed for cell growth.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02690948
The ClinicalTrials.gov registry entry for NCT02690948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02690948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02690948 about?
NCT02690948 is a clinical study titled "Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer". This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint inhibitors that stimulate im...
What is the current status of trial NCT02690948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-02-01. Estimated completion is 2018-08-29.
What interventions are being tested in trial NCT02690948?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT02690948?
This trial is sponsored by Anne Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.